vedicitumomab + pyrrolizidine

**Vedicitumomab + pyrrolizidine** is a non-specific and likely erroneous clinical-trial intervention label appearing in a Phase 1/2 study for HER2-expressing locally advanced or metastatic salivary duct carcinoma. In the associated study materials, vedicitumomab is described as the anti-HER2 MMAE antibody-drug conjugate RC48, which corresponds to disitamab vedotin. However, \"pyrrolizidine\" is a broad chemical-scaffold term rather than a uniquely identifiable therapeutic agent, so this exact combination cannot be reliably normalized to a defined two-drug regimen. The trial narrative separately describes an oral HER2 tyrosine-kinase inhibitor written as \"pyrrolitinib,\" indicating a probable data-entry or translation error, but that agent is not substituted here because it is not the exact input name. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05898373))

Other names

vedicitumomab + pyrrolizidine